Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Disease entities : Regulus therapeutics inc. save search
Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Published: 2024-03-12 (Crawled : 12:30) - biospace.com/
RGLS | $2.13 -4.05% -4.23% 220K
|
Health Technology
|
| O: 68.84%
H: 62.66%
C: 1.29%
rgls8429 disease kidney positive treatment topline trial therapeutics
Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Published: 2024-01-02 (Crawled : 21:00) - prnewswire.com
RGLS | $2.13 -4.05% -4.23% 220K
|
Health Technology
|
| O: 3.82%
H: 0.74%
C: -3.68%
rgls8429 disease kidney treatment trial therapeutics
Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Published: 2023-11-02 (Crawled : 14:00) - biospace.com/
RGLS | $2.13 -4.05% -4.23% 220K
|
Health Technology
|
| O: 1.63%
H: 8.0%
C: 8.0%
rgls8429 disease kidney treatment trial therapeutics
Regulus Therapeutics Advances to Cohort 3 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Published: 2023-10-19 (Crawled : 13:30) - biospace.com/
RGLS | $2.13 -4.05% -4.23% 220K
|
Health Technology
|
| O: 6.38%
H: 0.0%
C: -8.18%
rgls8429 disease kidney treatment trial therapeutics
Regulus Therapeutics Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Published: 2023-09-20 (Crawled : 15:00) - biospace.com/
RGLS | $2.13 -4.05% -4.23% 220K
|
Health Technology
|
| O: 3.03%
H: 3.53%
C: -22.94%
rgls8429 disease kidney positive treatment topline trial therapeutics
Regulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Published: 2023-09-13 (Crawled : 13:00) - biospace.com/
RGLS | $2.13 -4.05% -4.23% 220K
|
Health Technology
|
| O: 16.44%
H: 0.0%
C: -2.35%
rgls8429 disease kidney treatment trial therapeutics
Regulus Therapeutics Announces First Patient Dosed in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Published: 2023-06-27 (Crawled : 13:00) - biospace.com/
RGLS | $2.13 -4.05% -4.23% 220K
|
Health Technology
|
| O: -2.24%
H: 10.69%
C: 9.16%
rgls8429 disease kidney treatment trial therapeutics
Regulus Therapeutics Advances to Cohort 2 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Published: 2023-05-16 (Crawled : 13:00) - biospace.com/
RGLS | $2.13 -4.05% -4.23% 220K
|
Health Technology
|
| O: -2.58%
H: 1.32%
C: -3.97%
rgls8429 disease kidney treatment trial therapeutics
Regulus Therapeutics Announces Completion of Enrollment in First Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Published: 2023-04-12 (Crawled : 23:00) - biospace.com/
RGLS | $2.13 -4.05% -4.23% 220K
|
Health Technology
|
| O: -6.25%
H: 6.44%
C: 0.01%
rgls8429 disease kidney treatment trial therapeutics
Regulus Therapeutics Announces First Patient Dosed in Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Published: 2022-11-02 (Crawled : 17:00) - biospace.com/
RGLS | $2.13 -4.05% -4.23% 220K
|
Health Technology
|
| O: 1.44%
H: 0.0%
C: -9.38%
rgls8429 treatment disease kidney trial therapeutics phase 2b
Regulus Therapeutics Announces Positive Topline Safety and Pharmacokinetic (PK) Data from the Phase 1 Single-Ascending Dose (SAD) Clinical Trial of RGLS8429 for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Published: 2022-09-12 (Crawled : 14:20) - biospace.com/
RGLS | $2.13 -4.05% -4.23% 220K
|
Health Technology
|
| O: 11.31%
H: 28.34%
C: 3.74%
rgls8429 treatment disease topline kidney trial therapeutics positive
Polycystic Kidney Disease Drugs Market Report by Technavio predicts USD 510.69 Mn growth -- Driven by the high prevalence of chronic kidney diseases
Published: 2022-09-09 (Crawled : 11:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 4.47%
H: 0.0%
C: 0.0%
AZNCF | $138.24 -4.19% 800
|
Health Technology
|
| O: 5.77%
H: 0.0%
C: -2.47%
XRTX | $3.5 -3.05% -3.14% 12K
|
Mining, Quarrying, and Oil and ...
|
| O: -0.72%
H: 1.46%
C: -3.65%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 1.59%
H: 0.27%
C: 0.06%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 2.11%
H: 0.0%
C: 0.0%
RGLS | $2.13 -4.05% -4.23% 220K
|
Health Technology
|
| O: 3.12%
H: 3.03%
C: 1.82%
GLPG | $29.095 0.64% 0.64% 87K
|
Health Technology
|
| O: 0.47%
H: 0.0%
C: -1.31%
AZN | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 1.43%
H: 0.0%
C: -0.54%
disease report kidney growth market
Regulus Therapeutics Announces Receipt of FDA Orphan Drug Designation for RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Published: 2022-06-21 (Crawled : 16:00) - biospace.com/
RGLS | $2.13 -4.05% -4.23% 220K
|
Health Technology
|
| O: 3.45%
H: 0.0%
C: 0.0%
rgls8429 treatment fda designation drug disease kidney therapeutics
Regulus Therapeutics Announces First Subject Dosed in Phase 1 Single-Ascending Dose (SAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Published: 2022-06-13 (Crawled : 12:20) - prnewswire.com
RGLS | $2.13 -4.05% -4.23% 220K
|
Health Technology
|
| O: -1.79%
H: 3.05%
C: 1.7%
rgls8429 treatment disease kidney trial therapeutics phase 1
Regulus Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Published: 2022-05-11 (Crawled : 13:00) - biospace.com/
RGLS | $2.13 -4.05% -4.23% 220K
|
Health Technology
|
| O: 11.05%
H: 71.96%
C: 40.74%
rgls8429 treatment fda drug disease kidney application therapeutics
Regulus Therapeutics Announces Presentation at the First Annual Rare & Genetic Kidney Disease Drug Development Summit
Published: 2021-12-01 (Crawled : 14:30) - biospace.com/
RGLS | $2.13 -4.05% -4.23% 220K
|
Health Technology
|
| O: -1.94%
H: 1.32%
C: -4.71%
genetic drug therapeutics presentation disease kidney rare
Exploring the Role of MicroRNA in Genetic Kidney Disease Pathologies
Published: 2021-12-01 (Crawled : 12:30) - regulusrx.com
RGLS | $2.13 -4.05% -4.23% 220K
|
Health Technology
|
| O: -1.94%
H: 1.32%
C: -4.71%
genetic disease kidney
Regulus Therapeutics Presents Additional Data from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program at PKD Connect 2021
Published: 2021-06-25 (Crawled : 12:00) - biospace.com/
RGLS | $2.13 -4.05% -4.23% 220K
|
Health Technology
|
| O: 2.0%
H: 2.94%
C: -10.29%
disease kidney
Regulus Therapeutics to Present Additional Data from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program at PKD Connect 2021
Published: 2021-06-21 (Crawled : 12:00) - biospace.com/
RGLS | $2.13 -4.05% -4.23% 220K
|
Health Technology
|
| O: 3.55%
H: 10.99%
C: 9.32%
disease kidney
Regulus Therapeutics Announces Incremental Update of Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program
Published: 2021-05-21 (Crawled : 12:15) - prnewswire.com
RGLS | $2.13 -4.05% -4.23% 220K
|
Health Technology
|
| O: 1.83%
H: 5.15%
C: 2.49%
disease kidney
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.